| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T77645 | ||||
| Target Name | TRAIL receptor 1 (TRAIL-R1) | ||||
| Type of Target |
Clinical trial |
||||
| Action against Disease Model | RhApo2L/TRAIL | Drug Info | The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells. We generated a death receptor-4 (DR4)-expressing adenovirus (Ad-hTERT-DR4), in which the expression of DR4 is driven by the hTERT promoter. Upon infection, DR4 expression was slightly increased in cancer cell lines, and cell death was observed in TRAIL-resistant cancer cell lines but not in normal h uMan cells when DR4 infection was combined with TRAIL treatment. | [1] | |
| References | |||||
| REF 1 | The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells. Yonsei Med J. 2006 Feb 28;47(1):55-62. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.